These finding is not unexpected since GLP-1 may increase natriuresis through the inhibition of many ion exchangers in the tubules which expression decreases with the progression of CKD and interstitial fibrosis and tubular atrophy 33
In the context of GLP-1 analogs, nanoformulations have shown significant promise in addressing their inherent pharmacokinetic limitations
Moreover, small-molecule GLP-1RAs offer a solution to the bioavailability limitations faced by oral peptide-based agents, which often depend on absorption enhancers (e.g., SNAC) and strict fasting protocols [74]
A few hours at room temperature (68 to 77 degrees) is unlikely to cause significant degradation for most formulations
Using the Wrong Solvent: Reconstituting with tap water, distilled water, or any non-sterile liquid introduces bacteria and minerals that can contaminate and destabilize the peptide
Headache has been reported in 4%25% of patients using GLP-1 RAs 13